Conart Engineers Bags ₹15.41 Crore Construction Contract

Mumbai, May 27: Conart Engineers has secured a civil construction work order worth approximately ₹15.41 crore from Apothecon Pharmaceuticals Private for a project in Gujarat, according to an exchange filing.

The order relates to civil construction work for LVAPI-6 Services at Apothecon Pharmaceuticals’ facility located at Dabhasa in Padra, Vadodara district. The contract was received on Tuesday, May 26, the company said in its disclosure.

According to the filing, the project is scheduled to be executed within 12 months from the date of the purchase order. The contract value excludes GST and could vary depending on final layout modifications or any additional work awarded during project execution.

While not a transformative order in size, the contract adds to Conart’s project pipeline and reinforces its presence in the industrial and pharmaceutical construction segment, where execution capabilities and client relationships often lead to repeat business opportunities.

Stock Market Snapshot

Conart Engineers share price finished the session in positive territory after investors reacted to the announcement.

As of 3:30 PM IST on May 27, 2026, the stock was trading at ₹110.00, up ₹4.27 or 4.04% from the previous close of ₹105.73.

The stock touched ₹112.45 and a low of ₹102.90 before ending near the upper end of the day’s trading range.

The rise suggests investors viewed the order as another step in strengthening the company’s order book at a time when construction activity across industrial and manufacturing sectors continues to remain healthy.

Pharmaceutical Sector Continues To Drive Industrial Construction Demand

The latest contract comes from Apothecon Pharmaceuticals, a domestic pharmaceutical company expanding infrastructure at its Gujarat facility.

India’s pharmaceutical industry has remained an active source of demand for specialised construction contractors, particularly for manufacturing plants, utility facilities and support infrastructure that must comply with strict regulatory and operational standards.

For engineering and construction companies such as Conart, projects from pharmaceutical clients often provide opportunities to deepen relationships within a sector that continues to invest in capacity expansion and modernisation.

The company clarified that the order is domestic in nature and does not involve any related-party transaction or promoter interest.

Company Background

Conart Engineers is engaged in engineering, procurement and construction activities, with experience across industrial, commercial and institutional projects.

The company undertakes civil construction works for manufacturing facilities, industrial infrastructure and specialised projects requiring technical execution capabilities.

Over the years, Conart has built a presence across sectors including pharmaceuticals, manufacturing and industrial development, where project delivery timelines and execution quality remain key differentiators.

Conclusion

The ₹15.41 crore contract from Apothecon Pharmaceuticals adds fresh business visibility for Conart Engineers and strengthens its presence in the pharmaceutical infrastructure segment.

Although modest relative to larger EPC contracts seen in the industry, the order supports the company’s ongoing project pipeline and highlights continuing investment activity within India’s pharmaceutical manufacturing ecosystem.

Source:

• https://www.bseindia.com/stock-share-price/conart-engineers-ltd/conart/522231
• https://www.bseindia.com/xml-data/corpfiling/AttachLive/83f9ff79-8527-43f6-8015-7ee9ea8aa88a.pdf